Peter Mohr

Summary

Affiliation: Elbeklinikum Buxtehude
Country: Germany

Publications

  1. ncbi request reprint [Adjuvant interferon therapy in malignant melanoma]
    Peter Mohr
    Dermato Onkologie Elbe Klinikum Buxtehude, Dermatologisches Zentrum, Am Krankenhaus 1, Buxtehude, Germany
    J Dtsch Dermatol Ges 5:543-5. 2007
  2. doi request reprint Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial
    Peter Mohr
    Peter Mohr, Elbe Klinikum Buxtehude, Buxtehude Axel Hauschild and Michael Weichenthal, University Hospital Schleswig Holstein, Kiel Uwe Trefzer, Charite Universitatsmedizin Berlin, Berlin Alexander Enk, University Hospital Heidelberg, Heidelberg Wolfgang Tilgen, University Hospital, Homburg Saarland Carmen Loquai, University of Mainz, Mainz Thomas Haalck, Universitatsklinikum Hamburg Eppendorf, Hamburg Ralf Gutzmer, Hannover Medical School, Hannover Norbert Brockmeyer, Ruhr Universitat Bochum, Bochum Erhard Hölzle, Oldenburg Hospital, Oldenburg Cord Sunderkötter, University of Munster, Münster Cornelia Mauch, University of Cologne, Cologne Annette Stein, Universitatsklinikum Carl Gustav Carus, Dresden Lars A Schneider, University of Ulm, Ulm Maurizio Podda, Darmstadt Hospital, Darmstadt Daniela G uml oppner, University Hospital Magdeburg, Magdeburg Dirk Schadendorf, University Hospital Essen, Essen, Germany Helen Gogas
    J Clin Oncol 33:4077-84. 2015
  3. doi request reprint [Supportive care for malignant melanoma]
    P Mohr
    Elbeklinikum Buxtehude, Am Krankenhaus 1, 21614, Buxtehude, Deutschland
    Hautarzt 59:492-8. 2008
  4. doi request reprint Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
    Lisa Zimmer
    Department of Dermatology, University Hospital, University Duisburg Essen, Essen, Germany
    J Transl Med 13:351. 2015
  5. ncbi request reprint Adjuvant therapy in melanoma
    P Mohr
    Department of Dermatology, Elbeklinikum Buxtehude, Germany
    Onkologie 26:227-33. 2003
  6. pmc Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma
    Lisa Zimmer
    Department of Dermatology, University Hospital, University Duisburg Essen, Essen, Germany
    PLoS ONE 10:e0118564. 2015
  7. doi request reprint Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
    Henrike Tolk
    aDepartment of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover bCenter for Dermatology, Elbe Klinikum Buxtehude, Buxtehude cDepartment of Dermatology, University Hospital, University of Duisburg Essen, Essen dDepartment of Dermatology, University of Tuebingen, Tuebingen eDepartment of Dermatology, University of Rostock, Rostock, Germany
    Melanoma Res 25:362-6. 2015
  8. doi request reprint Electrical impedance spectroscopy as a potential adjunct diagnostic tool for cutaneous melanoma
    Peter Mohr
    Department of Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany
    Skin Res Technol 19:75-83. 2013
  9. pmc Staging of cutaneous melanoma
    P Mohr
    Elbekliniken, Buxtehude, Germany
    Ann Oncol 20:vi14-21. 2009
  10. doi request reprint Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up
    Selma Ugurel
    Authors Affiliations Department of Dermatology, University of Wurzburg, Würzburg Dermatopathology Bodensee, Friedrichshafen Skin Cancer Unit, German Cancer Research Center, Heidelberg Department of Dermatology, University Hospital Heidelberg, Heidelberg Department of Dermatology, University Medical Center Mannheim, University of Heidelberg, Mannheim Department of Dermatology, Martin Luther University, Halle Saale Department of Dermatology, Elbe Klinikum Buxtehude, Buxtehude Department of Dermatology, Saarland University Hospital, Homburg, Saarland Department of Dermatology, University Hospital of Munster, Münster Department of Dermatology, University of Kiel, Kiel Department of Dermatology, Technical University Munich, Munich Department of Dermatology, University Hospital Erlangen, Erlangen Department of Dermatology, HELIOS Klinikum Erfurt, Erfurt Department of Pathology, University of Gottingen, Göttingen Department of Dermatology, University of Essen, Essen, Germany and Department of Dermatology, Medical University Graz, Graz, Austria
    Clin Cancer Res 20:499-510. 2014

Collaborators

Detail Information

Publications13

  1. ncbi request reprint [Adjuvant interferon therapy in malignant melanoma]
    Peter Mohr
    Dermato Onkologie Elbe Klinikum Buxtehude, Dermatologisches Zentrum, Am Krankenhaus 1, Buxtehude, Germany
    J Dtsch Dermatol Ges 5:543-5. 2007
  2. doi request reprint Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial
    Peter Mohr
    Peter Mohr, Elbe Klinikum Buxtehude, Buxtehude Axel Hauschild and Michael Weichenthal, University Hospital Schleswig Holstein, Kiel Uwe Trefzer, Charite Universitatsmedizin Berlin, Berlin Alexander Enk, University Hospital Heidelberg, Heidelberg Wolfgang Tilgen, University Hospital, Homburg Saarland Carmen Loquai, University of Mainz, Mainz Thomas Haalck, Universitatsklinikum Hamburg Eppendorf, Hamburg Ralf Gutzmer, Hannover Medical School, Hannover Norbert Brockmeyer, Ruhr Universitat Bochum, Bochum Erhard Hölzle, Oldenburg Hospital, Oldenburg Cord Sunderkötter, University of Munster, Münster Cornelia Mauch, University of Cologne, Cologne Annette Stein, Universitatsklinikum Carl Gustav Carus, Dresden Lars A Schneider, University of Ulm, Ulm Maurizio Podda, Darmstadt Hospital, Darmstadt Daniela G uml oppner, University Hospital Magdeburg, Magdeburg Dirk Schadendorf, University Hospital Essen, Essen, Germany Helen Gogas
    J Clin Oncol 33:4077-84. 2015
    ..To evaluate the efficacy, safety, tolerability, and quality of life (QoL) in patients receiving intravenous, intermittent high-dose interferon alfa-2b (IFN-α-2b [iHDI]) compared with standard high-dose IFN-α-2b (HDI)...
  3. doi request reprint [Supportive care for malignant melanoma]
    P Mohr
    Elbeklinikum Buxtehude, Am Krankenhaus 1, 21614, Buxtehude, Deutschland
    Hautarzt 59:492-8. 2008
    ..Specific recommendations for all of these dermato-oncologic problems are provided in detail...
  4. doi request reprint Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
    Lisa Zimmer
    Department of Dermatology, University Hospital, University Duisburg Essen, Essen, Germany
    J Transl Med 13:351. 2015
    ....
  5. ncbi request reprint Adjuvant therapy in melanoma
    P Mohr
    Department of Dermatology, Elbeklinikum Buxtehude, Germany
    Onkologie 26:227-33. 2003
    ..Patients with high-risk malignant melanoma should preferentially be treated in prospective randomized multicenter trials to give more detailed data for treatment recommendations...
  6. pmc Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma
    Lisa Zimmer
    Department of Dermatology, University Hospital, University Duisburg Essen, Essen, Germany
    PLoS ONE 10:e0118564. 2015
    ..As patients with UM were excluded in these studies, the Dermatologic Cooperative Oncology Group (DeCOG) conducted a phase II to assess the efficacy and safety of ipilimumab in patients with metastatic UM...
  7. doi request reprint Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
    Henrike Tolk
    aDepartment of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover bCenter for Dermatology, Elbe Klinikum Buxtehude, Buxtehude cDepartment of Dermatology, University Hospital, University of Duisburg Essen, Essen dDepartment of Dermatology, University of Tuebingen, Tuebingen eDepartment of Dermatology, University of Rostock, Rostock, Germany
    Melanoma Res 25:362-6. 2015
    ..Discontinuation of BRAFi therapy after a CR has to be balanced carefully with the potential risk of nonresponding to BRAFi retreatment in the case of relapse. ..
  8. doi request reprint Electrical impedance spectroscopy as a potential adjunct diagnostic tool for cutaneous melanoma
    Peter Mohr
    Department of Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany
    Skin Res Technol 19:75-83. 2013
    ..Electrical impedance spectroscopy (EIS) may therefore be able to aid clinicians in differentiating between benign and malignant skin lesions...
  9. pmc Staging of cutaneous melanoma
    P Mohr
    Elbekliniken, Buxtehude, Germany
    Ann Oncol 20:vi14-21. 2009
    ....
  10. doi request reprint Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up
    Selma Ugurel
    Authors Affiliations Department of Dermatology, University of Wurzburg, Würzburg Dermatopathology Bodensee, Friedrichshafen Skin Cancer Unit, German Cancer Research Center, Heidelberg Department of Dermatology, University Hospital Heidelberg, Heidelberg Department of Dermatology, University Medical Center Mannheim, University of Heidelberg, Mannheim Department of Dermatology, Martin Luther University, Halle Saale Department of Dermatology, Elbe Klinikum Buxtehude, Buxtehude Department of Dermatology, Saarland University Hospital, Homburg, Saarland Department of Dermatology, University Hospital of Munster, Münster Department of Dermatology, University of Kiel, Kiel Department of Dermatology, Technical University Munich, Munich Department of Dermatology, University Hospital Erlangen, Erlangen Department of Dermatology, HELIOS Klinikum Erfurt, Erfurt Department of Pathology, University of Gottingen, Göttingen Department of Dermatology, University of Essen, Essen, Germany and Department of Dermatology, Medical University Graz, Graz, Austria
    Clin Cancer Res 20:499-510. 2014
    ..This trial investigated imatinib as neoadjuvant treatment of DFSP, including long-term follow-up...
  11. doi request reprint Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions
    Thomas K Eigentler
    Department of Dermatology, Center for Dermatooncology, University Medical Center Tübingen, Tübingen Department of Dermatology and Venerology, Skin Cancer Center and Center for Integrated Oncology, University Hospital of Cologne, CIO Köln Bonn Department of Dermatology, University Hospital Heidelberg, Heidelberg Department of Dermatology, University Hospital Mainz, Mainz Department of Dermatology, University Essen Duisburg, Essen Department of Dermatology and Allergy, Hannover Medical School, Hannover Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt Main Department of Dermatology, Elbe Kliniken Buxtehude, Buxtehude Medical Department, Technische Universitat, München Department of Dermatology, Zentralklinikum Augsburg, Augsburg Department of Dermatology, Harzklinikum Dorothea Christiane Erxleben, Quedlinburg Department of Dermatology, University Hospital Muenster, Münster Department of Dermatology, University Hospital Kiel, Kiel Department of Dermatology, University Hospital Homburg Saar, Homburg Saar Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
    J Immunother 37:374-81. 2014
    ..Here, the largest ever reported cohort treated with ipilimumab 3 mg/kg alone is described...
  12. ncbi request reprint Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial
    Karsten Neuber
    Department of Dermatology, University Hospital Hamburg, Martinistr 52, D 20246 Hamburg, Germany
    Melanoma Res 13:81-5. 2003
    ..The non-haematological toxicity of this outpatient regimen was mild. In conclusion, intravenous treosulfan treatment does not induce objective response rates when used as a second-line treatment of metastatic malignant melanoma...
  13. ncbi request reprint Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study
    Lutz Kowalzick
    Department of Dermatology and Allergy, Municipal Hospital Plauen, Box 100153, Germany
    Eur J Dermatol 12:558-61. 2002
    ..In addition, rIFN-beta-1a is safe and generally well tolerated. rIFN-beta-1a represents an effective alternative treatment for BETACC...